Published in Breast Cancer Res Treat on September 28, 2008
Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J (2012) 2.21
Perspectives for cancer prevention with natural compounds. J Clin Oncol (2009) 1.99
Chemoprevention of head and neck cancer with green tea polyphenols. Cancer Prev Res (Phila) (2010) 1.00
Green tea compounds in breast cancer prevention and treatment. World J Clin Oncol (2014) 0.83
The ubiquitin ligase TRAF6 negatively regulates the JAK-STAT signaling pathway by binding to STAT3 and mediating its ubiquitination. PLoS One (2012) 0.83
CUEDC2 (CUE domain-containing 2) and SOCS3 (suppressors of cytokine signaling 3) cooperate to negatively regulate Janus kinase 1/signal transducers and activators of transcription 3 signaling. J Biol Chem (2011) 0.83
Syzygium campanulatum korth methanolic extract inhibits angiogenesis and tumor growth in nude mice. BMC Complement Altern Med (2013) 0.82
Chemoprevention of oral cancer: Green tea experience. J Nat Sci Biol Med (2014) 0.77
An Ethanolic Extract of Ampelopsis Radix Exerts Anti-colorectal Cancer Effects and Potently Inhibits STAT3 Signaling In Vitro. Front Pharmacol (2017) 0.75
Extracellular vesicles-mediated noncoding RNAs transfer in cancer. J Hematol Oncol (2017) 0.75
High dose of green tea infusion normalized spiral artery density in rats treated with the depot-medroxyprogesterone acetate. J Intercult Ethnopharmacol (2016) 0.75
Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med (1995) 26.60
Stat3 as an oncogene. Cell (1999) 17.39
The STATs of cancer--new molecular targets come of age. Nat Rev Cancer (2004) 13.07
Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J (2003) 10.77
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene (2002) 6.17
Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res (2002) 5.84
Suppressors of cytokine signaling and immunity. Nat Immunol (2003) 3.68
Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol (2005) 2.96
Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol (2002) 2.80
Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci U S A (2004) 2.25
Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res (2006) 2.11
Stats: multifaceted regulators of transcription. J Interferon Cytokine Res (2005) 2.02
Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev (2005) 1.93
Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res (2005) 1.82
Curcumin is an in vivo inhibitor of angiogenesis. Mol Med (1998) 1.81
Evaluation of potential Stat3-regulated genes in human breast cancer. Biochem Biophys Res Commun (2005) 1.76
High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res (2001) 1.70
Green tea, black tea and breast cancer risk: a meta-analysis of epidemiological studies. Carcinogenesis (2005) 1.66
Roles and regulation of stat family transcription factors in human breast cancer. Am J Pathol (2004) 1.64
Green tea inhibits vascular endothelial growth factor (VEGF) induction in human breast cancer cells. J Nutr (2002) 1.48
EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells. Br J Cancer (2001) 1.41
Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer (1997) 1.40
[6]-Gingerol, a pungent ingredient of ginger, inhibits angiogenesis in vitro and in vivo. Biochem Biophys Res Commun (2005) 1.39
Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction. J Exp Ther Oncol (2002) 1.36
Tumor gelatinases and invasion inhibited by the green tea flavanol epigallocatechin-3-gallate. Cancer (2001) 1.26
Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control (2002) 1.25
Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation. Cancer Res (2002) 1.20
Role of epigallocatechin gallate (EGCG) in the treatment of breast and prostate cancer. Life Sci (2006) 1.18
Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis. Cancer Epidemiol Biomarkers Prev (2003) 1.18
Tea catechins inhibit angiogenesis in vitro, measured by human endothelial cell growth, migration and tube formation, through inhibition of VEGF receptor binding. Cancer Lett (2002) 1.17
Mechanisms of inhibition of tumor angiogenesis and vascular tumor growth by epigallocatechin-3-gallate. Clin Cancer Res (2004) 1.15
VEGF-targeted therapy: therapeutic potential and recent advances. Oncologist (2005) 1.13
Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells. Clin Cancer Res (2003) 1.07
Green tea catechin, epigallocatechin-3-gallate, inhibits vascular endothelial growth factor angiogenic signaling by disrupting the formation of a receptor complex. Int J Cancer (2006) 1.07
Chemoprevention of lung cancer by tea. Mol Nutr Food Res (2006) 1.05
Inhibition of mammary tumorigenesis in the C3(1)/SV40 mouse model by green tea. Breast Cancer Res Treat (2007) 1.00
Green tea catechins inhibit VEGF-induced angiogenesis in vitro through suppression of VE-cadherin phosphorylation and inactivation of Akt molecule. Int J Cancer (2003) 0.99
New TNF-alpha releasing inhibitors as cancer preventive agents from traditional herbal medicine and combination cancer prevention study with EGCG and sulindac or tamoxifen. Mutat Res (2003) 0.96
Recruitment of histone deacetylase 4 to the N-terminal region of estrogen receptor alpha. Mol Endocrinol (2005) 0.94
Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584. Semin Oncol (2003) 0.92
Green tea extract inhibits angiogenesis of human umbilical vein endothelial cells through reduction of expression of VEGF receptors. Life Sci (2003) 0.91
Green tea catechins and vitamin E inhibit angiogenesis of human microvascular endothelial cells through suppression of IL-8 production. Nutr Cancer (2001) 0.90
Anti-angiogenic therapy in breast cancer. Biomed Pharmacother (2003) 0.86
Epigallocatechin-3-gallate inhibits the PDGF-induced VEGF expression in human vascular smooth muscle cells via blocking PDGF receptor and Erk-1/2. Int J Oncol (2006) 0.85
Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife (2013) 3.49
NFkappaB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses. Nat Chem Biol (2008) 2.44
Plasma membrane estrogen receptors exist and functions as dimers. Mol Endocrinol (2004) 2.00
Ligand control of coregulator recruitment to nuclear receptors. Annu Rev Physiol (2005) 1.87
Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat Struct Biol (2002) 1.83
Structural basis for an unexpected mode of SERM-mediated ER antagonism. Mol Cell (2005) 1.50
Structural plasticity in the oestrogen receptor ligand-binding domain. EMBO Rep (2007) 1.47
MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun (2013) 1.43
Elemental isomerism: a boron-nitrogen surrogate for a carbon-carbon double bond increases the chemical diversity of estrogen receptor ligands. Chem Biol (2007) 1.31
Allosteric control of ligand selectivity between estrogen receptors alpha and beta: implications for other nuclear receptors. Mol Cell (2004) 1.24
An estrogen receptor-alpha knock-in mutation provides evidence of ligand-independent signaling and allows modulation of ligand-induced pathways in vivo. Endocrinology (2008) 1.16
CBP Is a dosage-dependent regulator of nuclear factor-kappaB suppression by the estrogen receptor. Mol Endocrinol (2007) 1.09
MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion. Breast Cancer Res Treat (2012) 1.07
Identification of ligands with bicyclic scaffolds provides insights into mechanisms of estrogen receptor subtype selectivity. J Biol Chem (2006) 1.04
Conformation-specific affinity purification of proteins using engineered binding proteins: application to the estrogen receptor. Protein Expr Purif (2005) 1.03
Structure-guided optimization of estrogen receptor binding affinity and antagonist potency of pyrazolopyrimidines with basic side chains. J Med Chem (2007) 1.01
Inhibition of mammary tumorigenesis in the C3(1)/SV40 mouse model by green tea. Breast Cancer Res Treat (2007) 1.00
Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort. BMC Cancer (2009) 0.96
Label-free detection of protein-protein interactions on biochips. Angew Chem Int Ed Engl (2005) 0.95
Recruitment of histone deacetylase 4 to the N-terminal region of estrogen receptor alpha. Mol Endocrinol (2005) 0.94
Estrogen-dependent and -independent estrogen receptor-alpha signaling separately regulate male fertility. Endocrinology (2009) 0.88
Nuclear receptor ligands and cofactor recruitment: is there a coactivator "on deck"? Mol Cell (2003) 0.84
Modulation of alphaCaMKII signaling by rapid ERalpha action. Brain Res (2008) 0.83
Prolactin activates ERα in the absence of ligand in female mammary development and carcinogenesis in vivo. Endocrinology (2013) 0.82
The effects of 17β-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis. Gynecol Oncol (2011) 0.82
Molecular characterization of a B-ring unsaturated estrogen: implications for conjugated equine estrogen components of premarin. Steroids (2007) 0.81
Targeting protein tyrosine kinase 6 enhances apoptosis of colon cancer cells following DNA damage. Mol Cancer Ther (2012) 0.80
In vivo imaging reveals estrogen receptor's hidden personality. Nat Med (2003) 0.80
Mapping ERβ genomic binding sites reveals unique genomic features and identifies EBF1 as an ERβ interactor. PLoS One (2013) 0.80
Examining the pathogenesis of breast cancer using a novel agent-based model of mammary ductal epithelium dynamics. PLoS One (2013) 0.79
Cross-talk between the ligand- and DNA-binding domains of estrogen receptor. Proteins (2013) 0.78
In memoriam: Elwood Jensen (1920-2012). Endocrinology (2013) 0.77
Removal of lactate dehydrogenase-elevating virus from human-in-mouse breast tumor xenografts by cell-sorting. J Virol Methods (2011) 0.76
The Neutron Enigma. Sci Am (2016) 0.75
In memoriam: Elwood Jensen (1920-2012). Endocr Rev (2013) 0.75